𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Interferon-ribavirin-nonresponders in chronic hepatitis C — should we retreat?

✍ Scribed by M. Wiese; U. Kullig; A. Herrmann; H. Porst

Book ID
117372100
Publisher
Elsevier Science
Year
2003
Tongue
English
Weight
164 KB
Volume
38
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Merimepodib, pegylated interferon, and r
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders
✍ Vinod K. Rustgi; William M. Lee; Eric Lawitz; Stuart C. Gordon; Nezam Afdhal; Fr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB 👁 1 views

on behalf of the MErimepodib TRiple cOmbination (METRO) study group Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-a